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John J V McMurray, MD, FRCP, FESC (Work Group Co-
Chair), is Professor of Medical Cardiology at BHF Glasgow
Cardiovascular Research Centre and Head of Section of
Academic Cardiology at University of Glasgow. Dr McMur-
ray received his medical degree from University of Manche-
ster and completed additional clinical training in Edinburgh,
Dundee and Glasgow. He conducts clinical research in a wide
span of areas including heart failure, left ventricular
dysfunction, coronary heart disease, diabetes, and kidney
failure. As such, Dr McMurray is a member of the Executive
Committee or Steering Committee for a number of large
ongoing multinational trials: ARISTOTLE, ASCEND-HF,
ASPIRE, ATMOSPHERE, Dal-OUTCOMES, EMPHASIS-
HF, NAVIGATOR, PARADIGM-HF, RED-HF, TREAT and
VIVIDD. He is also Past President of the Heart
Failure Association of the European Society of Cardiology
and has authored close to 500 original publications,
reviews, and book chapters. Dr McMurray is currently
on a number of journal editorial boards including:
Cardiovascular Drugs and Therapy, Circulation: Heart Failure,
European Heart Journal, European Journal of Heart Failure,
Heart, Heart Failure Reviews, International Journal of
Cardiology and Journal of the Renin-Angiotensin-Alderosterone
System.
Dr McMurray0s employer, Glasgow University, received
support from Amgen for his role as Executive Committee
member of clinical trials (RED-HF; TREAT; ATOMIC-HF).
Dr McMurray0s salary from his employer is independent
from the monies received by Glasgow University from
commercial or non-commercial organizations
Patrick S Parfrey, MD, FRCPC, FRSC (Work Group Co-
Chair), is a University Research Professor at Memorial
University and staff nephrologist at Eastern Health, New-
foundland. Dr Parfrey received his medical degree from
University College Cork, Ireland and is active in clinical
epidemiology research in kidney disease, particularly as it
relates to cardiovascular disease, anemia and genetic diseases.
He also supervised post-graduate work of more than 50
students and has authored over 300 publications. Dr Parfrey
is past Associate Editor of CJASN, past president of the
Canadian Society of Nephrology, an Officer of the Order of
Canada and Fellow of the Royal Society of Canada and has
received financial support from both Amgen and Ortho
Biotech, as Chair of the Data Monitoring Committee of the
Normal Hematocrit Study; Co-Primary Investigator of the
Canada–Europe Trial; Executive Committee Member of
TREAT; and Co-Chair of the Executive Committee of
EVOLVE.
Grant/Research Support: Amgen
Speaker: Amgen
John W Adamson, MD, completed his undergraduate work
at the University of California, Berkeley, and received a MD
degree from UCLA. Following training in Internal Medicine
and Hematology at the University of Washington, he spent
two years at the NIH, returning to the faculty in Seattle in
1969. He rose through the ranks to become professor and
head of the Division of Hematology in 1980 and was named a
Clinical Research Professor of the American Cancer Society
in 1988. In 1989, he moved to New York City as President of
the New York Blood Center and director of its research
institute. In 1998 he moved to Milwaukee as Executive Vice
President for Research at the Blood Center of Wisconsin and
Director of its Blood Research Institute. Four years ago he
joined the faculty at the University of California, San Diego,
as Clinical Professor of Medicine in Hematology/Oncology
where he serves as head of the Hematology/Oncology section
at the VA Medical Center and Associate Director of the
Hematology/Oncology Fellowship program at UCSD. Dr
Adamson has published numerous scientific articles and
reviews and has previously served as Editor-in-Chief of Blood;
founding editor of Current Opinion in Hematology; President
of the American Society of Hematology; and President of the
International Society for Experimental Hematology. His
interests lie in the areas of anemia diagnosis and manage-
ment, pathophysiology of the myeloproliferative neoplasms,
and the molecular biology of iron metabolism.
Advisor/Consultant: Affymax; Akebia; AMAG; Amgen;
Hospira; Watson
Speaker: AMAG; Watson
Pedro Aljama, MD, PhD, received his MD from the
University of Cadiz in 1971 and PhD from the University
of Seville in 1975. Professor Aljama then continued his
training at the Royal Victoria lnfirmary, Newcastle, United
Kingdom, where he was a Medical Officier, Registrar and
then Senior Registrar in Nephrology, and a Lecturer in Renal
Medicine at the University of Newcastle upon Tyne
(1977–1979). He returned to Spain in 1980 as a Senior
Registrar at Reina Sofia Hospital, University of Cordoba, and
was appointed Professor of Medicine and Nephrology in
1987. He is past President of the Spanish Society of
Nephrology and presently a member of the International
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Society of Nephrology, the European Society for Clinical
Investigation, the British Society of Nephrology and the
European Renal Association-European Dialysis and Trans-
plant Association. Professor Aljama has authored over 250
scientific papers and 50 book chapters.
Advisor/Consultant: Amgen; Roche; Vifor
Grant/Research Support: Janssen-Cilag; Roche
Speaker: Amgen; Vifor
Jeffrey S Berns, MD, is Professor of Medicine at the
Perelman School of Medicine at the University of Pennsylva-
nia and the Penn Presbyterian Medical Center of Philadel-
phia, University of Pennsylvania Health System. Dr Berns is
also the Associate Dean for Graduate Medical Education,
Nephrology Fellowship Program Director and Associate
Chief of Renal, Electrolyte and Hypertension Division at
the University of Pennsylvania Health System. He obtained
his medical degree from Case Western Reserve University and
completed his nephrology fellowship at Yale University
School of Medicine. His professional activities include his
service as a long-standing Work Group member of the
KDOQI Anemia guideline from 1995–2007 and currently he
is the KDOQI Vice Chair for Guideline Commentaries and
Updates and also a member of the National Quality Forum
ESRD Steering Committee. Dr Berns has authored over 130
publications and is on the editorial board of Clinical
Nephrology, CJASN, and Seminars in Dialysis. In recognition
for his contributions, he received the Leonard Berwick
Memorial Teaching Award in 2008 and the Penn Medicine
Patient Advocacy Award in 2010.
Advisor/Consultant: Affymax; Amgen; Takeda
Julia Bohlius, MD, MScPH, is a physician who is trained in
both hematology/oncology and public health. Dr Bohlius is
Editor of the Cochrane Haematological Malignancies Group
and has experience in the conduct of both literature-based and
individual patient data meta-analyses. Since 2001 she is a
leading systematic reviewer on ESAs in cancer patients and has
worked on international health technology assessments and
clinical guideline projects for ESAs and other growth factors in
cancer patients. While she started her clinical and scientific
career at the University of Cologne, Germany, she now works
as a Senior Research Fellow at the Institute of Social and
Preventive Medicine, University of Bern, Switzerland.
Dr Bohlius reported no relevant financial relationships
Tilman B Dru¨eke, MD, FRCP, is Emeritus Director of
Research at the INSERM laboratory ERI-12, UFR de
Me´decine et Pharmacie, Universite´ de Picardie Jules Verne,
Amiens, France. He received his MD degree at the University
of Tu¨bingen Medical School, Germany in 1968. From 1969
through 2009, he practiced his medical and scientific
activities at Necker Hospital/Necker Medical School, Uni-
versite´ Paris V, Paris, France. Professor Dru¨eke’s research
interests focus on chronic renal failure, hemodialysis,
metabolic and endocrine abnormalities, anemia, cardiovas-
cular complications and arterial hypertension. He is a
member of several scientific societies, committees and
advisory boards and a former Co-Chair of the KDIGO
CKD-MBD Guideline Work Group. Professor Dru¨eke is
Editor Emeritus of Nephrology Dialysis Transplantation,
former Associate Editor of the CJASN, an editorial board
member of JASN and presently Associate Editor of Kidney
International. He has published more than 500 original
articles and reviews in peer-reviewed journals.
Advisor/Consultant: Amgen; Roche; Vifor
Speaker: Amgen; Chugai; Vifor
Fredric O Finkelstein, MD, obtained his medical degree
from Columbia University and completed his nephrology
fellowship at Yale University Medical School where he is also
presently a Clinical Professor of Medicine. Over the span of
his career, he has lectured extensively throughout the world
and has held more than 30 visiting teaching positions. In
addition, he is currently Chair of the International Liaison
Committee of the International Society of Peritoneal Dialysis.
He is also Co-Chair of the Dialysis Committee of the
International Society of Nephrology and an author of over
200 publications. Dr Finkelstein has dedicated substantial
research towards the understanding of quality of life and
psychosocial issues for dialysis and non-dialysis patients
alike. He has served on the editorial board of Peritoneal
Dialysis International since 2004 and Kidney International
since 2010.
Advisor/Consultant: Akebia, Amgen; Baxter
Grant/Research Support: Amgen
Steven Fishbane, MD, received his medical degree from Albert
Einstein College of Medicine where he also completed his
nephrology fellowship. He is currently Vice President of the
North Shore-LIJ Health System in Manhasset, NY, as well as
Professor of Medicine at SUNY Stony Brook School of
Medicine. Dr Fishbane is the Director of Clinical Trials for
the Department of Medicine of North Shore-LIJ University
Hospitals. Having participated as a KDOQI Anemia Guideline
Work Group member, he maintains an active research interest
in this area and has written over 150 publications. In addition
to serving as a reviewer for numerous journals, he currently sits
on the editorial board of CJASN and Kidney International. In
recognition for his commitment on enhancing healthcare
delivery and assessment, Dr Fishbane was the recipient of the
Physician Leadership in Quality Improvement Award from
IPRO in 2002 and the Volunteerism Award of the National
Kidney Foundation Serving Greater New York in 2010.
Advisor/Consultant: Affymax; Akebia; Fibrogen; Rockwell
Medical Technologies
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Tomas Ganz, PhD, MD, is Professor of Medicine and Pathology
at the David Geffen School of Medicine at UCLA. Dr Ganz
received his PhD from the California Institute of Technology in
Applied Physics and MD from UCLA. He was then trained
in Internal Medicine and Pulmonary/Critical Care Medicine at
the UCLA Medical Center. His major focus was on research on
the biological role of peptide mediators in innate immunity and
iron metabolism. More recently, he has investigated the
pathogenesis of anemia of inflammation and iron overload
states, and worked on the development of hepcidin agonists and
antagonists. Dr Ganz has served as an Associate Editor of Blood
and a member of the Erythrocyte and Leukocyte Biology (ELB)
Study Section of the National Institutes of Health. In 2005, he
received the Marcel Simon Award of the International Bioiron
Society for the discovery of hepcidin.
Advisor/Consultant: Alnylam; Intrinsic LifeSciences;
Merganser Biotech; Ortho Biotech/Centocor; Pieris; Xenon;
Employee: Intrinsic LifeSciences; Merganser Biotech
Equity Interest: Intrinsic LifeSciences; Merganser Biotech
Grant/Research Support: Amgen; Xenon
Iain C Macdougall, BSc, MD, FRCP, is a Consultant
Nephrologist and Professor of Clinical Nephrology at King’s
College Hospital, London, UK. He is a combined medical
and science graduate of Glasgow University, Scotland, from
which he was awarded a First Class Honours BSc in
Pharmacology in 1980, and his medical degree in 1983.
Professor Macdougall then completed his general medical
and nephrology training at hospitals in Glasgow, Cardiff, and
London. He developed a research interest in renal anemia
while a Clinical Research Fellow in Cardiff (1988–1991) and
extended this interest during his appointment at St
Bartholomew’s Hospital (1991–1996), where he studied the
potential role of proinflammatory cytokines in mediating
resistance to epoetin. He has been involved in numerous
advisory boards in renal anemia management worldwide,
including the Working Parties responsible for both the 1999
and the 2004 versions of the European Best Practice
Guidelines, along with the Work Group that produced the
latest US KDOQI Anemia Guidelines (2006; update 2007).
He was a previous Board member of the KDIGO initiative,
and a Council member of the European Renal Association
from 2004 until 2007. He has been the UK lead on several
pivotal clinical trials of anemia management in patients with
chronic kidney disease, including CREATE and TREAT, and
he chairs the Anaemia Clinical Study Group of the UK
Kidney Research Consortium.
Advisor/Consultant: Affymax; Amgen; Ortho Biotech; Roche;
Takeda; Vifor
Grant/Research Support: Affymax; Amgen; Vifor
Speaker: Amgen; Ortho Biotech; Takeda; Vifor
Ruth A McDonald, MD, is Professor of Pediatrics at
University of Washington and Clinical Director of Nephrol-
ogy at Children’s Hospital and Regional Medical Center in
Seattle, Washington. She completed her medical degree at
University of Minneosta School of Medicine where she was a
recipient of the Top Medical Graduate: Hewlett-Packard
Award. Dr McDonald is currently involved in numerous
multicenter clinical studies including a controlled trial of
Anti-CD20 monoclonal antibody therapy in historically
unsensitized renal transplant recipients with donor-specific
antibodies; a Phase II study to determine safety and
immunomodulatory functions of induction therapy with
Campath 1H, combined with mycophenolate mofetil and
sirolimus; a surveillance study of viral infections in renal
transplant recipients and many others. She is also a member
of eight professional organizations including American
Society of Pediatric Nephrology, American Society of
Transplantation, International Pediatric Transplant Associa-
tion and past Work Group member of the KDIGO Clinical
Practice Guideline for the Care of Kidney Transplant
Recipients. Among her teaching responsibilities, she has
trained over 25 fellows and has also served as Medical
Student Research Mentor. Dr McDonald has authored over
60 publications and has given close to 40 invited and extra-
institutional lectures in the past 10 years.
Dr McDonald reported no relevant financial relationships
Lawrence P McMahon, MBBS, MD, is Director, Department
of Renal Medicine at Eastern Health Integrated Renal Services
and Professor Nephrology at Monash University. Prior to his
present appointments, he was Associate Professor at
University of Melbourne School of Medicine; Director of
Nephrology Services and Obstetric Medical Services at
Western Health; and Consortium Director of Physician
Training at Greater Western Consortium. Dr McMahon has
participated in guideline development activities for the
Australian and New Zealand Society of Nephrology and is
presently the President, National Council of Society of
Obstetric Medicine of Australian and New Zealand. He has
written more than 50 publications and serves as a regular
reviewer for more than a dozen journals, including his role as
Associate Editor of Nephrology Dialysis Transplantation.
Grant/Research Support: Amgen; Roche
Gregorio T Obrador, MD, MPH, is Professor of Medicine
and Dean at the Universidad Panamericana School of
Medicine in Mexico City. He also serves as Adjunct Physician
at the Tufts Medical Center’s Division of Nephrology and as
staff nephrologist at Dalinde Medical Center in Mexico City.
He earned his medical degree from the University of Navarra,
Pamplona, Spain, completed his Internal Medicine residency
at the Western Pennsylvania Hospital, Pittsburgh, USA, and
obtained his Nephrology training at Boston University, USA.
While undertaking a clinical research fellowship at the Tufts-
New England Medical Center and a Master of Public Health
at Harvard University, he demonstrated that the management
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of patients with CKD prior to stage 5 is suboptimal, and
that this is an important factor for the high morbidity and
mortality observed in these patients. He has been a
member of the KDOQI’s Advisory Board, the NKF/KDOQI
Anemia Work Goup, and the KDIGO Transplant Guideline
Work Group. Currently he is a member of the WHO’s
Non-Communicable diseases Network (NCDnet), Co-Chair
of the Global Kidney Disease Prevention Network (KDPN),
Co-Chair of the Latin American Clinical Practice Guidelines
for the Prevention, Diagnosis and Treatment of CKD (Stages
1–5), and President of the Board of Directors of the
Mexican Kidney Foundation. In 2009 he received the
National Kidney Foundation’s International Distinguished
Medal. Dr Obrador is a member of the editorial board of
CJASN and has served as reviewer for other nephrology
journals. He has given more than 100 lectures in national and
international forums and has several publications in the area
of CKD.
Grant/Research Support: Amgen; Roche
Giovanni FM Strippoli, MD, PhD, MPH, is a nephrologist
and an epidemiologist trained both in Italy and at the
University of Sydney School of Public Health, Sydney,
Australia where he completed a Master of Public Health
and a PhD in medicine-clinical epidemiology. Dr Strippoli is
an editor of the Cochrane Renal Group, and Adjunct
Associate Professor of Epidemiology at the School of Public
Health, and the Renal Research Coordinator at Mario Negri
Sud Consortium in Italy. He also serves as scientific director
of Diaverum AB. His research interests include evidence-
based nephrology, with a focus on systematic reviews in the
area of prognosis and treatment of renal conditions, design
and conduct of randomized controlled trials in the field
of prevention of chronic kidney disease and cardiovascular
risk. Dr Strippoli has a substantial scientific output with
independent funding in these areas. He is also the principal
investigator of LIRICO, a trial on the Long Term Impact of
Renin Angiotensin System Inhibitors on Cardiorenal Out-
comes in people with albuminuria, and C.E. DOSE, a trial on
the clinical evaluation of the Dose of Erythropoietins in
people on hemodialysis.
Employee: Diaverum AB
Gu¨nter Weiss, MD, is Professor of Clinical Immunology and
Infectious Diseases, Department of Internal Medicine, and
Head of research laboratory for Molecular Immunology
and Infectious Diseases at Medical University of Innsbruck.
Dr Weiss had enrolled in Leopold Franzens University and
University of Innsbruck for his medical studies and his
ongoing research encompasses a wide array of topics
including: anemia of chronic disease; primary and secondary
iron overload; host pathogen interaction with a particular
focus on the role of macrophages and natural resistance
genes; and regulatory interactions between iron, immunity
and infection. Dr Weiss has authored 190 original publica-
tions in peer reviewed journals including reviews on anemia
of chronic disease and iron metabolism in inflammation and
infection.
Grant/Research Support: Amgen
Speaker: Vifor
Andrzej Wie˛cek, MD, PhD, FRCP, is Professor of Internal
Medicine and Chief, Department of Nephrology, Endocri-
nology and Metabolic Diseases, at Silesian University
School of Medicine, Katowice, Poland. Dr Wie˛cek’s research
interests include anemia management in CKD, treatments for
primary and secondary hypertension, elucidation of hormo-
nal abnormalities in uremia, and endocrine function of
adipose tissue. In addition to being a participating member
of the European Renal Best Practice Anaemia Working
Group, he is Past President of Polish Society of Nephrology
and has served on the KDIGO Board. Dr Wie˛cek is now a
member of KDIGO Implementation Task Force Leader
for Eastern Europe region and Secretary-Treasurer for the
ERA-EDTA. As a prolific author with over 530 publications,
he is currently Subject Editor for Nephrology Dialysis
Transplantation.
Advisor/Consultant: Abbott; Affymax; Sandoz
Speaker: Amgen
KDIGO CHAIRS
Bertram L Kasiske, MD, is Professor of Medicine at the
University of Minnesota, USA. He received his medical
degree from the University of Iowa and completed his
Internal Medicine residency and fellowship training in
Nephrology at Hennepin County Medical Center where he
is currently Director of Nephrology.
Dr Kasiske is former Deputy Director of the United States
Renal Data System and former Editor-in-Chief of The
American Journal of Kidney Diseases. He has served as
Secretary/Treasurer and on the Board of Directors of the
American Society of Transplantation, and on the Organ
Procurement and Transplantation Network/United Network
of Organ Sharing Board of Directors, and the Scientific
Advisory Board of the National Kidney Foundation. He is
currently serving on the Board of Councilors of the
International Society of Nephrology. He is the Principal
Investigator for a National Institutes of Health-sponsored,
multi-center study of long term outcomes after kidney
donation. He is the Director of the Scientific Registry of
Transplant Recipients. He has over 160 scientific publications
in major peer reviewed journals, and 230 review articles,
editorials and textbook chapters. Dr Kasiske is also a recipient
of the NKF’s Garabed Eknoyan Award in 2003.
Advisor/Consultant: Litholink
Grant/Research Support: Bristol-Myers Squibb; Merck-
Schering Plough
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David C Wheeler, MD, FRCP, holds an academic position
in Nephrology (Reader) at University College London, UK
and is an Honorary Consultant Nephrologist at the Royal
Free Hospital. His research is focused on the cardiovascular
complications of chronic kidney disease and the role of
vascular risk factors in progression of kidney damage. Dr
Wheeler is a member of the International Steering Commit-
tee of the Study of Heart and Renal Protection (SHARP) and
was UK National Coordinator for the trial. He is involved in
several other randomized trials and observational studies
involving patients with chronic kidney disease.
He currently serves on the executive committee of KDIGO
and previously contributed as a Work Group member to the
KDIGO Guideline on Chronic Kidney Disease-Mineral and
Bone Disorder. He has recently received an International
Distinguished Medal from the US National Kidney Founda-
tion in recognition of his contribution to guideline develop-
ment. In the UK, he has previously served on the executive
committee of the Renal Association and has been elected
President for the term 2012–2014.
Dr Wheeler has served on the editorial boards of the
American Journal of Kidney Diseases and Journal of the
American Society of Nephrology and currently acts as co-
Deputy Editor for Nephrology Dialysis Transplantation.
Advisor/Consultant: Amgen
Honoraria: Abbott, Amgen, Fresenius, Shire
Grant/Research Support: Abbott, Genzyme
EVIDENCE REVIEW TEAM
Ethan M Balk, MD, MPH, is Director, Evidence-based
Medicine at the Tufts Center for Kidney Disease Guideline
Development and Implementation, in Boston, MA, USA,
Associate Director of the Tufts Evidence-based Practice
Center, and Assistant Professor of Medicine at Tufts
University School of Medicine. Dr Balk graduated from
Tufts University School of Medicine and completed a
fellowship in Clinical Care Research. As Project Director, he
plays a substantial role in providing methodological expertise
in the guideline development process and assists in the
collection, evaluation, grading, and synthesis of evidence and
the revisions of the final evidence report. Dr Balk also
provides methodological guidance and training of Work
Group members during meetings regarding topic refinement,
key question formulation, data extraction, study assessment,
evidence grading, and recommendation formulation. His
primary research interests are evidence-based medicine,
systematic review, clinical practice guideline development,
and critical literature appraisal.
Dr Balk reported no relevant financial relationships
Ashish Upadhyay, MD, is Assistant Professor, Renal Section
and Associate Director, Internal Medicine Residency Program
at Boston University School of Medicine, Boston, MA, USA.
Dr Upadhyay was previously Assistant Professor at Tufts
University School of Medicine and staff physician in the
William B. Schwartz, MD, Division of Nephrology at Tufts
Medical Center. He joined the ERT in July 2009 and served as
the Assistant Project Director for the KDIGO Management of
Blood Pressure in CKD and Anemia in CKD Guidelines. Dr
Upadhyay coordinated and assisted in the collection, evalua-
tion, grading, and synthesis of evidence, and played a critical
role in the revisions of the final evidence report. He also
provided methodological guidance and training of Work
Group members on topic refinement, key question formula-
tion, data extraction, study assessment, evidence grading, and
recommendation formulation. Dr Upadhyay’s past research
involved studying kidney disease epidemiology in the Framing-
ham Heart Study. He has published in areas ranging from
arterial stiffness in CKD and inflammation in kidney disease to
dialysis complications and epidemiology of hyponatremia.
Dr Upadhyay reported no relevant financial relationships
Dana C Miskulin, MD, MS, is Assistant Professor of Medicine
at Tufts University School of Medicine, Boston, MA, USA. She
completed a fellowship in Clinical Care Research and
participated in the conduct of systematic reviews and critical
literature appraisals for this guideline. Her primary research
interests are in comparative effectiveness research in dialysis
patients, blood pressure treatment in dialysis patients, and
autosomal dominant polycystic kidney disease.
Dr Miskulin reported no relevant financial relationships
Amy Earley, BS, is a project coordinator at the Tufts Center
for Kidney Disease Guideline Development and Implementa-
tion in Boston, MA, USA. She is key in coordinating the
guideline development activities within the ERT, especially in
the development of the evidence reports for all guidelines. Ms
Earley also heads the actual evidence review, which includes
running searches, screening, data extraction, drafting of
tables and methods sections, proofing of guideline drafts and
critical literature appraisals. She participates in the conduct
of research projects at the Center and actively collaborates
with other members of the Center on independent research
topics and manuscript submissions.
Ms Earley reported no relevant financial relationships
Shana Haynes, MS, DHSc, is a research assistant at the Tufts
Center for Kidney Disease Guideline Development and
Implementation in Boston, MA, USA. She participates in
all aspects of evidence review and guideline development.
She screens abstracts and articles, extracts data, and assists in
the drafting and editing of evidence tables. Dr Haynes
also assists in the development of clinical practice guidelines
and conducts systematic reviews and critical literature
appraisals.
Dr Haynes reported no relevant financial relationships
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Jenny Lamont, MS, is a project manager and medical writer
at the Tufts Center for Kidney Disease Guideline Development
and Implementation in Boston, MA, USA. She participates in
all aspects of evidence review and guideline development,
assists in the preparation of talks and manuscripts, and edits
KDIGO draft guidelines currently in progress.
Ms Lamont reported no relevant financial relationships
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